Posters
Outcomes of phacoemulsification in irido-fundal coloboma eyes with cataract
Poster Details
First Author: J.Jinagal INDIA
Co Author(s): G. Gupta J. Ram M. Akella
Abstract Details
Purpose:
Cataract surgery in eyes with iridofundal coloboma is a challenge and is associated with many complications. Previously only few reports are available showing outcome of phacoemulsification with posterior chamber intraocular lens (PCIOL) implantation. To study the visual outcomes of phacoemulsification in cataractous eyes with iridofundal coloboma and prognostic factors affecting the outcomes.
Setting:
Retrospective medical record analysis done at tertiary eye care hospital in northern India.Advanced Eye Centre, Post Graduate Institution of Medical Education and research, Chandigarh, India.
Methods:
Medical records of patients of iridofundal coloboma who underwent phacoemulsification between January 2010 to December 2017, with minimum postoperative follow up of 1 year, were reviewed. Primary outcome measure was best corrected visual acuity (BCVA) at postoperative 1 month and 1 year. Preoperatively, slit-lamp findings including type and grade of cataract, clock hours of iris coloboma, grade of coloboma were also analyzed.
Results:
39 eyes of 30 patients were included. Mean preoperative LogMar BCVA was 1.42±0.36 and mean postoperative LogMar BCVA at 1 month was 1.12±0.44 (P-value<0.0001) and at 1 year was 1.016±0.44 (P-value<0.0001). Post-operatively LogMar BCVA significantly improved in both the groups with iris coloboma ≤1 or >1 clock hour (P-value<0.01) but this was more in patients with iris coloboma extending ≤1 clock hour (P-value<0.05). Hard cataract was associated with more chances of posterior capsular rupture and retinal detachment.
Conclusions:
Phacoemulsification with posterior chamber intraocular lens implantation results in good visual outcome in cases of iridofundal coloboma with cataract. Soft to moderate grade of cataract has better outcome than hard cataract. Extent of clock hour of iris coloboma can be a useful prognostic factor.
Financial Disclosure:
None
